Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | FABP3 | P05413 | 2/20 | 0.32 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29353263 | 1.00 | ROCK2 (0.35) | ROCK2GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL28313352 | 0.98 | ROCK2 (0.34) | ROCK2GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL19928426 | 0.94 | ROCK2 (0.32) | ROCK2 | |
| SCHEMBL29912661 | 0.94 | ROCK2 (0.32) | ROCK2 | |
| SCHEMBL29946397 | 0.91 | FABP3 (0.41) | FABP3FABP4FABP5 | |
| Acetonitrile SCHEMBL30092421 | 0.87 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL28465642 | 0.86 | FABP3 (0.38) | FABP3FABP4FABP5PDK2 | |
| Trifluoromethanesulfonic Acid SCHEMBL28465644 | 0.86 | GPR3 (0.36) | FABP3FABP4FABP5 | |
| Phenethylamine SCHEMBL21198481 | 0.86 | HTR2A (0.37) | — | |
| SCHEMBL4003562 | 0.86 | ROCK2 (0.37) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6033 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146125-A1 | LADDER POLYMERS AND IMPROVED METHODS OF MAKING THE SAME | OSMOSES INC. (US) | 2026-05-28 | — | — | US | claimed |
| WO-2026086030-A1 | METHOD FOR CONSTRUCTING CHIRALITY OF PYRAN RING IN ORFORGLIPRON BY MEANS OF ENZYMATIC CATALYSIS | 成都安迈博生物医药有限公司 | 2026-04-30 | — | — | WO | claimed |
| US-20260062361-A1 | PROCESS FOR THE PREPARATION OF BIO-BASED OLEFINS FROM PRIMARY ALCOHOL | BASF SE (DE) | 2026-03-05 | — | — | US | claimed |
| EP-4678632-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | AGC Inc. (JP) | 2026-01-14 | — | — | EP | claimed |
| US-20250388564-A1 | METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS | EDGEWISE THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | claimed |
| US-20250346557-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | AGC Inc. (JP) | 2025-11-13 | — | — | US | claimed |
| EP-4634171-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | F. Hoffmann-La Roche AG (CH) | 2025-10-22 | — | — | EP | claimed |
| US-20250313551-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2025-10-09 | — | — | US | claimed |
| EP-4601774-A1 | LADDER POLYMERS AND IMPROVED METHODS OF MAKING THE SAME | Osmoses Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| US-20250197380-A1 | PHARMACEUTICAL INTERMEDIATE AND SYNTHESIS METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHESIS METHOD THEREFOR | BANGENTAI(SHANDONG) BIOSCIENCES GROUP SHARE CO., LTD. (CN) | 2025-06-19 | — | — | US | claimed |
| US-20120116109-A1 | PREPARATION OF A METAL COMPLEX | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-05-10 | — | — | US | claimed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | claimed |
| US-7531695-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICAL, INC (US) | 2009-05-12 | — | — | US | claimed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | claimed |
| EP-1636160-A4 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | claimed |